| Content |
Issue date |
Issue |
- Increased risk of Cardiovascular Events & Cardiovascular Mortality when Hydroxychloroquine or Chloroquine used with Macrolide antibiotics
|
4/2022 |
DHPC Azithromycin interaction with hydroxychloroquine
|
- PAXLOVID Emergency Use Authorization (EUA) dosing and dispensing in moderate
renalimpairment, and risk of serious adverse reactions due to drug interactions
|
3/2022 |
DHPC Paxlovid used in Covid
|
- Anagrelide hydrochloride: Risk of thrombosis including cerebral infarction upon abrupt treatment discontinuation
|
3/2022 |
DHPC Anagrelide
|
- Mavenclad (Cladribine) – risk of serious liver injury and new recommendations about liver function monitoring
|
3/2022 |
DHPC Cladribine
|
- Infliximab: Use of live vaccines in infants exposed in utero or during breastfeeding
|
3/2022 |
DHPC Infliximab
|
- Levocetirizine shouldn’t be used in children less than 2 years
|
2/2022 |
DHPC Levocetirizine
|
- Important Safety Information Regarding Use of Molnupiravir in Pregnancy and Individuals of Childbearing Potential
|
2/2022 |
DHPC Molnupiravir
|
- Octreotide Solution for Subcutaneous injection and intravenous infusion: Risk of atrioventricular block
|
2/2022 |
DHPC Octreotide
|
- Olsalazine – Severe cutaneous adverse reactions, including Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN), drug reaction with eosinophilia and systemic symptoms (DRESS), and acute generalized exanthematous pustulosis (AGEP)
|
2/2022 |
DHPC Olsalazine
|
- Donepezil-QTc interval extension and Torsade de Pointes
|
1/2022 |
DHPC Donepezil
|
- Glatiramer Acetate: Rare cases of severe liver damage
|
1/2022 |
DHPC Glatiramer
|
- Amiodarone Hydrochloride 50 mg/ml concentrate for solution for
Injection/Infusion - Potential for crystallisation
|
1/2022 |
DHPC Amiodarone |
- Dapagliflozin 5mg should no longer be used for the treatment of Type 1 Diabetes Mellitus
|
1/2022 |
DHPC Dapagliflozin |
- Dinoprostone: Add A Restriction On Use And Update Of Dosage Recommendations, Warnings And Especially Adding Recommendations On The Risks Of Hyperstimulation Uterine, Uterine Rupture And Fetal / Neonatal Mortality
|
1/2022 |
DHPC Dinoprostone
|
- COVID-19 mRNA Vaccine Spikevax (previously Moderna): risk of myocarditis and pericarditis
|
11/2021 |
DHPC for Moderna concerning pericarditis
|
- COVID-19 mRNA Vaccine Comirnaty: risk of myocarditis and pericarditis
|
11/2021 |
COVID-19 mRNA Vaccine Comirnaty: risk of myocarditis and pericarditi
|
- COVID-19 Vaccine AstraZeneca: Risk of thrombocytopenia (including immune thrombocytopenia) with or without associated bleeding
|
10/2021 |
COVID-19 Vaccine AstraZeneca Risk of thrombocytopenia
|
- COVID-19 Vaccine Janssen: Risk for immune thrombocytopenia (ITP) and venous thromboembolism (VTE)
|
10/2021 |
COVID-19 Vaccine Janssen Risk for immune thrombocytopenia
|
- COVID-19 Vaccine AstraZeneca: contraindication in individuals with previous capillary leak syndrome
|
6/2021 |
COVID-19 Vaccine AstraZeneca contraindication |
- It was noted that the dosing information (specifically the timing of dosing with respect to food) in the product information for the levodopa-containing products was not optimal: it did not make clear that dosing without food is possible, and maybe preferable for some patients.
|
6/2021 |
Updating Dosing Information Levodopa |
- COVID-19 Vaccine Janssen: Contraindication in individuals with previous capillary leak syndrome and update on thrombosis with thrombocytopenia syndrome
- Capillary leak syndrome (CLS)
- Thrombosis with thrombocytopenia syndrome(TTS)
|
6/2021 |
J&J Covid 19 Vaccine
Risk Of Capillary Leak Syndrome And TTS
|
- COVID-19 Vaccine AstraZeneca: Risk of thrombosis in combination with
thrombocytopenia — Updated information .
|
6/2021 |
Astrazeneca Covid 19 Vaccine Risk Of TTS update June 2021
|
- Tofacitinib: initial clinical trial results of increased risk of major adverse cardiovascular events and malignancies (excluding NMSC) with use of tofacitinib relative to TNF-alpha inhibitors.
|
4/2021 |
Tofacitinib Updated safety information
|
- COVID-19 Vaccine AstraZeneca: Risk of coagulation disorders with or
without thrombocytopenia
|
4/2021 |
AstraZeneca Covid 19 Vaccine Risk Of TTS April 2021
|
- As the leaflets available in the packs of Leflunomide tablets are currently undergoing important safety updates, we would like to inform you of these important safety updates till their implementation in packs.
|
3/2021 |
Leflunomide Safety Updates
|